Feed Top Reports Pricing

⌘K

16:07:10·21d

SECFiling

SEC Form DEFA14A filed by Personalis Inc.

PSNL· Personalis Inc.

Health Care

Original source

Companies

PSNL
Personalis Inc.
Health Care

Recent analyst ratings

Dec 2UpdateMorgan Stanley$11.00
May 15UpdateGuggenheim$6.00
Mar 17UpdateCanaccord Genuity$8.00
Feb 6UpdateNeedham$8.00
Feb 6UpdateNeedham-
Feb 25UpdateOppenheimer$24.00

Related

PR12h
Personalis to Announce First Quarter 2026 Financial Results
PR2d
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
PR10d
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
SEC21d
SEC Form DEF 14A filed by Personalis Inc.
PR22d
Personalis to Participate in the 25th Annual Needham Virtual Conference
INSIDER37d
CFO AND COO Tachibana Aaron was granted 34,375 shares, increasing direct ownership by 21% to 198,833 units (SEC Form 4)
INSIDER37d
SVP and Chief Legal Officer Moore Stephen Michael was granted 28,125 shares, increasing direct ownership by 44% to 92,325 units (SEC Form 4)
INSIDER37d
Chief Executive Officer Hall Christopher M was granted 87,500 shares, increasing direct ownership by 59% to 235,986 units (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022

SEC Form DEFA14A filed by Personalis Inc. | Quantisnow